This article is more than 5 years old. Information may no longer be current.

Carl Zeiss Meditec reports 7.3% revenue growth in Q2

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Carl Zeiss Meditec reported an increase in revenue to €673.7 million, corresponding to a growth of 7.3% after adjusting for exchange rates, according to a company press release.

Taking into account the negative impact from currency translation effects present in previous quarters, the company’s revenue increased by 3.8% compared with the same period in 2013.

Translation effects also impacted growth in earnings before interest and taxes (EBIT; €92.1 million) and the EBIT margin (13.7%); however, the 9-month report signified neutral results from currency-hedging transactions, equating to 13.5% reductions in earnings per share, according to the release.

The Surgical Ophthalmology SBU recorded the strongest revenue growth (22%), due to the acquisition of Aaren Scientific. Microsurgery SBU revenues increased only slightly, with surgical microscopes and visualization solutions increasing by 5.9%, according to the release.

Ophthalmic Systems SBU was able to keep its revenues at almost the previous year’s level, the company reported. Adjustments for currency translations led to a 3.6% growth, with demand for innovative lasers for refractive surgery.